MAIN BODY
Unprecedented progression-free survival and overcoming acquired resistance
Published online by The Lancet on October 26, 2026, the phase 3 double-blind investigation examined an exceptionally difficult-to-treat patient population in which 98% had stage 4 non-small-cell lung cancer and all had exhausted third-generation EGFR targeted therapies. Once patients develop acquired resistance to targeted tyrosine kinase inhibitors, cytotoxic chemotherapy historically remained the sole, marginally effective therapeutic recourse.










